The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)
Our aim in this study is to investigate the potential role of serum ProCT as an early diagnostic marker and later prognostic indicator for VAP.
|Study Design:||Time Perspective: Prospective|
|Official Title:||The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)|
- Cases with VAP and high ProCT and Cases with Non-VAP and Low ProCT [ Time Frame: Retrospective chart review after results are available ] [ Designated as safety issue: No ]
|Study Start Date:||July 2007|
|Study Completion Date:||May 2009|
Device: PROCALCITONIN LEVEL
measuring PROCALCITONIN LEVEL
Ventilator-associated pneumonia (VAP), a bacterial infection that develops after 48 hours or more of intubation, is associated with high morbidity and mortality. Rapid identification of VAP is required to improve survival and to reduce avoidable treatment-associated side effects. Procalcitonin (ProCT), a blood test, is a reasonably specific marker of bacterial infection and its level increases early in sepsis. In this study, a ProCT serum level will be measured in 50 patients with clinically suspected VAP. We aim to show that the ProCT level will be high early in VAP and will stay high in patients with poor prognosis. This will help to address the potential role of ProCT as part of early diagnosis and management of VAP.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00498121
|McGill University Health Centre|
|Montreal, Quebec, Canada, H3A 1A1|
|Principal Investigator:||Salman A Qureshi, MD,FRCPSC||McGill University Health Center|